Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1994 Nov;38(6):411–416. doi: 10.1007/BF01517212

Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism

Ofer Merimsky 1,2, Yehuda Shoenfeld 3, Galit Yecheskel 2, Samario Chaitchik 1, Esther Azizi 4, Pnina Fishman 2,✉
PMCID: PMC11038539  PMID: 8205563

Abstract

The significance of the association between the appearance of hypopigmentation in patients with melanoma and the prognosis is still not clear. It was postulated that, in melanoma, an immune response is responsible for the destruction of the malignant as well as the normal pigmented cells, and that the eventual development of vitiligo-like patches in melanoma patients improves their prognosis. We studied the level of anti-melanoma antibodies in the sera of patients with melanoma with hypopigmentation and compared it to the titer in patients with melanoma only, to the titer of patients with vitiligo, and to that of healthy subjects. Only IgG-type antibodies were found in the sera of patients with vitiligo, with melanoma, or with melanoma with hypopigmentation. No significant differences in the titer of anti-melanoma antibodies could be found between the patients with melanoma when subgrouped according to the initial stage and the status of the disease at the time when the test was carried out. Statistically significantly (P<0.001) higher titers of antibodies were detected in the sera of patients with vitiligo in comparison to the lower titers in the other groups. Our results point to a similar immunobiological status, which probably does not give any advantage to patients with melanoma with hypopigmentation compared to patients without it. The appearance of hypopigmentary plaques in melanoma patients should be regarded, in our opinion, as a concomitant immunological phenomenon of the disease.

Key words: Malignant melanoma, Vitiligo, Hypopigmentation, Anti-melanoma antibodies, Marker, Melanoma-associated antigens

Footnotes

This work was supported by a grant given by the Israeli Chief Scientist, Ministry of Health, Israel

References

  • 1.Alexander MA, Lee W, Guerry D. Retroviral vector transfection of a class II positive human metastatic melanoma cell line with a matched HLA-DR beta-1 gene restores its capacity to present antigens. Proc Annu Meet Am Assoc Cancer R. 1991;32:1413A. [Google Scholar]
  • 2.Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A22-restricted cytotoxic T cell clones from melanoma patients. J Exp Me. 1993;77:989. doi: 10.1084/jem.177.4.989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Betterle C, Del Prete GF, Peserico A, Bersani G, Caracciolo F, Trisotto A, Poggi F. Autoantibodies in vitiligo. Arch Dermatol. 1976;112:1328. [PubMed] [Google Scholar]
  • 4.Brostoff J, Bor S, Feiwel M. Autoantibodies in patients with vitiligo. Lancet. 1969;11:177. doi: 10.1016/s0140-6736(69)91421-4. [DOI] [PubMed] [Google Scholar]
  • 5.Bystryn JC. Serum antibodies in vitiligo patients. Clin Dermatol. 1989;7:136. doi: 10.1016/0738-081x(89)90063-1. [DOI] [PubMed] [Google Scholar]
  • 6.Bystryn JC, Naughton GK. Immunity to pigmented cells in vitiligo and melanoma. Fed Proc. 1984;43:1664. [Google Scholar]
  • 7.Bystryn JC, Naughton GK. The significance of vitiligo antibodies. J Dermatol. 1985;12:1. doi: 10.1111/j.1346-8138.1985.tb01532.x. [DOI] [PubMed] [Google Scholar]
  • 8.Bystryn JC, Rigel D, Friedman RJ, Kopf A. The prognostic significance of of vitiligo in patients with melanoma. Arch Dermatol. 1987;123:1053. [PubMed] [Google Scholar]
  • 9.Donaldson RC, Canaan SA, McLean R, Ackerman LV. Uveitis and vitiligo associated with BCG treatment for malignant melanoma. Surgery. 1974;76:771. [PubMed] [Google Scholar]
  • 10.Dunston GM, Halder RM. Vitiligo is associated with HLA-DR4 in black patients: a preliminary report. Arch Dermatol. 1990;126:56–60. [PubMed] [Google Scholar]
  • 11.Fishman P, Azizi E, Shoenfeld Y, Sredni B, Yecheskel G, Zigelman R, Chaitchik S, Floro S, Djaldetti M (1993) Vitiligo autoantibodies are effective against melanoma. Cancer (in press) [DOI] [PubMed]
  • 12.Foley LM, Lowe NJ, Mischelhoff E, Tiwari JL. Association of HLA-DR4 with vitiligo. J Am Acad Dermatol. 1983;8:39–42. doi: 10.1016/s0190-9622(83)80279-5. [DOI] [PubMed] [Google Scholar]
  • 13.Galbraith GMP, Miller D, Emerson DL. Western Blot Analysis of serum antibody reactivity with human melanoma cell antigens in alopecia areata and vitiligo. Clin Immunol Immunopathol. 1988;48:317–324. doi: 10.1016/0090-1229(88)90025-6. [DOI] [PubMed] [Google Scholar]
  • 14.Gupta RK, Morton DL. Detection of 90KD glycoprotein antigen containing immune complexes in sera of melanoma patients using an enzyme immunoassay. FASEB J. 1991;5:A1355. [Google Scholar]
  • 15.Harning R, Cui J, Bystryn JC. Realtion between the incidence and level of pigmented cell antibodies and disease activity in vitiligo. J Invest Dermatol. 1991;97:1078. doi: 10.1111/1523-1747.ep12492607. [DOI] [PubMed] [Google Scholar]
  • 16.Hertz KC, Gazze LA, Charles AB, Kirkpatrick H, Karz SL. Autoimmune vitiligo detection of antibodies to melanin producing cells. N Engl J Med. 1977;297:634. doi: 10.1056/NEJM197709222971204. [DOI] [PubMed] [Google Scholar]
  • 17.Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA. Common expression of melanoma tumor associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen. J Immunother. 1991;10:153–164. [PubMed] [Google Scholar]
  • 18.Hornung MO, Krementz EXT. Specific tissue and tumor responses of chimpanzees following immunization against human melanoma. Surgery. 1974;75:477. [PubMed] [Google Scholar]
  • 19.Koh HK, Sober AJ, Nakagawa H, Albert DM, Mihm MC, Fitzpatrick TB. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol. 1983;9:696. doi: 10.1016/s0190-9622(83)70183-0. [DOI] [PubMed] [Google Scholar]
  • 20.Laucius JF, Mastrangelo MJ. Human malignant melanoma. Philadelphia: Grunne & Straton; 1979. Cutaneous depigmentary phenomena in patients with malignant melanoma; p. 209. [Google Scholar]
  • 21.Lerner AB, Cage CW. Melanoma in horses. Yale J Biol Med. 1973;46:650. [PMC free article] [PubMed] [Google Scholar]
  • 22.Lerner AB, Nordlund J. Should vitiligo be induced in patients after resection of primary melanoma? Arch Dermatol. 1977;113:421. [PubMed] [Google Scholar]
  • 23.Lewis MG, Ikonopisov RL, Nairn RC, Phillips TM, Hamilton-Fairley G, Bodenham DC, Alexander P. Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J. 1969;3:547. doi: 10.1136/bmj.3.5670.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Lewis MG, Phillips TM, Cook KB, Blake J. Possible explanation for loss of detectable antibody in patients with disseminated malignant melanoma. Nature. 1971;232:52. doi: 10.1038/232052a0. [DOI] [PubMed] [Google Scholar]
  • 25.McBurney EL. Vitiligo: clinical picture and pathogenesis. Arch Intern Med. 1979;139:1295. doi: 10.1001/archinte.139.11.1295. [DOI] [PubMed] [Google Scholar]
  • 26.Moellman GE, Krass P, Halaban R. On the subject of serum antibodies to melanocytes in vitiligo. J Invest Dermatol. 1985;84:333. [Google Scholar]
  • 27.Morton DL, Eilber RJ, Joseph WL, Wood EC, Traham E, Ketcham AS. Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann Surg. 1970;172:740. doi: 10.1097/00000658-197010000-00018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, Irie RF. Prolongation of survival in metastatic melanoma after active specific immunization with a new polyvalent melanoma vaccine. Ann Surg. 1992;216:463. doi: 10.1097/00000658-199210000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Naughton G, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol. 1986;15:978. doi: 10.1016/s0190-9622(86)70260-0. [DOI] [PubMed] [Google Scholar]
  • 30.Nordlund JJ, Lerner AB. Vitiligo: it is important. Arch Dermatol. 1982;118:5. doi: 10.1001/archderm.118.1.5. [DOI] [PubMed] [Google Scholar]
  • 31.Nordlung JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983;9:689. doi: 10.1016/s0190-9622(83)70182-9. [DOI] [PubMed] [Google Scholar]
  • 32.Old LJ, Stockert E, Boyse EA, Kim JH. Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med. 1968;127:523. doi: 10.1084/jem.127.3.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Ortonne JP, Gauthier Y, Guillet G, Gauthier O. Depigmentation cutanée associée au melanoma malin. Ann Dermatol Venerol. 1978;105:1043. [PubMed] [Google Scholar]
  • 34.Shoenfeld Y, Isenberg D. The mosaic of autoimmunity. Amsterdam: Elsevier; 1988. pp. 1–550. [Google Scholar]
  • 35.Soubiran P, Benzaken S, Lellet C. Vitiligo peripheral T cell subset imbalance as defined by monoclonal antibodies. Vr J Dermatol. 1985;113(Suppl 28):124–125. doi: 10.1111/j.1365-2133.1985.tb15640.x. [DOI] [PubMed] [Google Scholar]
  • 36.Swissa M, Amital-Teplizki H, Haim N, Cohen Y, Shoenfeld Y. Autoantibodies in neoplasia: an unresolved enigma. Cancer. 1990;65:2554. doi: 10.1002/1097-0142(19900601)65:11<2554::aid-cncr2820651126>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES